Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
CRANBURY, N.J. and CAMBRIDGE, Mass., Nov. 6, 2012 /PRNewswire/ — Oncobiologics, Inc. and Boston Oncology, LLC today announced a strategic partnership that will allow Boston Oncology to license, manufacture, and commercialize four of Oncobiologics’ biosimilar therapies for cancer and immunological disease in the Middle East and North African (MENA) regions.
Under the agreement, Boston Oncology—a pharmaceutical company that localizes advanced technologies and manufacturing expertise in the developing world—will provide Oncobiologics with upfront licensing payments and development milestone payments, along with royalties after the medicines are commercialized. Boston Oncology plans to oversee clinical trials and the development of manufacturing facilities for these therapies in various MEN...